悦康药业：子公司YKYY018雾化吸入剂 获得FDA临床试验批准

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) to proceed with clinical trials for its inhalation aerosol YKYY018, aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Group 1 - The full subsidiary of the company, Beijing YKYY Technology Co., Ltd., is responsible for the development of YKYY018 [1] - The FDA issued a "Study May Proceed Letter" with IND number 178457, indicating regulatory approval for the clinical trial [1]